Bayer - Big Pharma's Q2 2010 Earnings Report


  • Further growth in sales and underlying EBITDA primarily driven by MaterialScience, Consumer Health as well as positive currency effects.
  • Price +1.3%, volume +7.9%, currency +6.0%, portfolio -0.6%
  • Special items due to partial write-down of Zevalin (-€132 million) and litigation (BHC -€57 million, BCS: -€66 million)
  • Currency impact on underlying EBITDA of approx. €160 million
  • Core EPS up 9.5%
  • Double-digit increase in net cash flow - working capital management further optimized
  • Increase in net financial debt mainly due to the dividend payment, annual payments of variable compensation, interest payments (occur mainly in Q2) and negative currency effects of €0.6 billion.
  • Significantly higher investments in R&D - R&D budget raised to €3.1 billion
  • Group outlook 2010 confirmed - subgroup outlook updated

See J&J's current stock quote from CNN Money

Bayer's website:
Full release: Bayer's earnings release

Bayer - Big Pharma's Q2 2010 Earnings Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.